Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation

References

• Abdel-Aziz MT, Williams K. 1969. Metabolism of 17-alpha-ethynylestradiol and its 3-methyl ether by the rabbit; an in vivo D-homoannulation. Steroids. 13:809–820.
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz MT, Williams K. 1970. Metabolism of radioactive 17alpha-ethynylestradiol by women. Steroids. 15:695–710.
   PubMed Web of Science ®Google Scholar
• Battioni P, Mahy JP, Delaforge M, Mansuy P. 1983. Reaction of monosubstituted hydrazines and diazenes with rat-liver cytochrome P450. Eur J Biochem. 134:241–248.
   PubMedGoogle Scholar
• Blakey DC, White I. 1986. Destruction of cytochrome P-450 and formation of green pigments by contraceptive steroids in rat hepatocyte suspensions. Biochem Pharmacol. 35:1561–1567.
   PubMed Web of Science ®Google Scholar
• Blanksby SJ, Ellison GB. 2003. Bond dissociation energies of organic molecules. Acc Chem Res. 36:255–263.
   PubMed Web of Science ®Google Scholar
• Blobaum AL. 2006. Mechanism-based inactivation and reversibility: is there a new trend in the inactivation of cytochrome P450 enzymes? Drug Metab Dispos. 34:1–7.
   PubMed Web of Science ®Google Scholar
• Blobaum AL, Harris DL, Hollenberg PF. 2005. P450 active site architecture and reversibility: inactivation of cytochromes P450 2B4 and 2B4 T302A by tert-butyl acetylenes. Biochemistry. 44:3831–3844.
   PubMed Web of Science ®Google Scholar
• Blobaum AL, Kent UM, Alworth WL, Hollenberg PF. 2002. Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein. Chem Res Toxicol. 15:1561–1571.
   PubMed Web of Science ®Google Scholar
• Blobaum AL, Kent UM, Alworth WL, Hollenberg PF. 2004a. Novel reversible inactivation of cytochrome P450 2E1 T303A by tert-butyl acetylene: the role of threonine 303 in proton delivery to the active site of cytochrome P450 2E1. J Pharmacol Exp Therap. 310:281–290.
   PubMed Web of Science ®Google Scholar
• Blobaum AL, Lu Y, Kent UM, Wang S, Hollenberg PF. 2004b. Formation of a novel reversible cytochrome P450 spectral intermediate: role of threonine 303 in P450 2E1 inactivation. Biochemistry. 43:11942–11952.
   PubMed Web of Science ®Google Scholar
• Burger A, Roussel JP, Colobert F, Kappler C, Hetru C, Luu B, Hoffmann JA. 1987. In vitro studies on potential selective and irreversible inhibitors of enzymes involved in the biosynthesis of ecdysone. Pest Biochem Physiol. 29:197–208.
   Web of Science ®Google Scholar
• CaJacob CA, Chan WK, Shephard E, Ortiz de Montellano PR. 1988. The catalytic site of rat hepatic lauric acid omega-hydroxylase. Protein versus prosthetic heme alkylation in the omega-hydroxylation of acetylenic fatty acids. J Biol Chem. 263:18640–18649.
   PubMed Web of Science ®Google Scholar
• Chan WK, Sui Z, Ortiz de Montellano PR. 1993. Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene. Chem Res Toxicol. 6:38–45.
   PubMed Web of Science ®Google Scholar
• Coelho PS, Brustad EM, Kannan A, Arnold FH. 2013. Olefin cyclopropanation via carbene transfer catalyzed by engineered cytochrome P450 enzymes. Science. 339:307–310.
   PubMed Web of Science ®Google Scholar
• Correia MA, Hollenberg PF. 2015. Inhibition of cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450: structure, mechanism, and biochemistry. 4th ed. New York (NY): Springer; p. 177–260.
   Google Scholar
• Cutler AJ, Rose PA, Squires TM, Loewen MK, Shaw AC, Quail JW, Krochko JE, Abrams SR. 2000. Inhibitors of abscisic acid 8'-hydroxylase. Biochemistry. 39:13614–13624.
   PubMed Web of Science ®Google Scholar
• Delorme C, Piffeteau A, Sobrio F, Marquet A. 1997. Mechanism-based inactivation of bovine cytochrome P-45011 by 18-unsaturated progesterone derivatives. Eur J Biochem. 248:252–260.
   PubMedGoogle Scholar
• El Masri AM, Smith JN, Williams RT. 1958. The metabolism of alkylbenzenes: phenylacetylene and phenylethylene (styrene). Biochem J. 68:199–204.
   PubMed Web of Science ®Google Scholar
• Ervin KM, Gronert S, Barlow SE, Gilles MK, Harrison AG, Bierbaum VM, DePuy CH, Lineberger WC, Ellison GB. 1990. Bond strengths of ethylene and acetylene. J Am Chem Soc. 112:5750–5759.
   Web of Science ®Google Scholar
• Fan PW, Gu C, Marsh SA, Stevens JC. 2003. Mechanism-based inactivation of cytochrome P450 2B6 by a novel terminal acetylene inhibitor. Drug Metab Dispos. 31:28–36.
   PubMed Web of Science ®Google Scholar
• Felig J, Barnes JR, Rachlin AI, O’Brien JP, Focella A. 1970. Substituted phenyl 2-propynyl ethers as carbamate synergists. J Agric Food Chem. 18:78–80.
   Web of Science ®Google Scholar
• Foroozesh M, Primrose G, Guo Z, Bell LC, Alworth WL, Guengerich FP. 1997. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Chem Res Toxicol. 10:91–102.
   PubMed Web of Science ®Google Scholar
• Freudenthal RI, Amerson E, Martin J, Wall ME. 1974. The effect of norethynodrel, norethindrone and ethynodiol diacetate on hepatic microsomal drug metabolism. Pharmacol Res Commun. 6:457–468.
   PubMedGoogle Scholar
• Gay SC, Zhang H, Wilderman PR, Roberts AG, Liu T, Li S, Lin H, Zhang Q, Woods VL, Stout CD, et al. 2011. Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: Insight into partial enzymatic activity. Biochemistry. 50:4903–4911.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. 1988. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol. 33:500–508.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. 1990. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol. 3:363–371.
   PubMed Web of Science ®Google Scholar
• Guilard R, Kadish M. 1988. Some aspects of organometallic chemistry in metalloporphyrin chemistry: synthesis, chemical reactivity, and electrochemical behavior of porphyrins with metal-carbon bonds. Chem Rev. 88:1121–1146.
   Web of Science ®Google Scholar
• Hammons GJ, Alworth WL, Hopkins NE, Guengerich FP, Kadlubar FF. 1989. 2-Ethynylnaphthalene as a mechanism-based inactivator of the cytochrome P450 catalyzed N-oxidation of 2-naphthylamine. Chem Res Toxicol. 2:367–374.
   PubMed Web of Science ®Google Scholar
• He K, Woolf TF, Hollenberg PF. 1999. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther. 288:791–797.
   PubMed Web of Science ®Google Scholar
• Helton ED, Williams MC, Goldzieher JW. 1977. Oxidative metabolism and de-ethynylation of 17-ethynylestradiol by baboon liver microsomes. Steroids. 30:71–83.
   PubMed Web of Science ®Google Scholar
• Helvig C, Alayrac C, Mioskowski C, Koop D, Poullain D, Durst F, Salaün JP. 1997. Suicide inactivation of cytochrome P450 by midchain and terminal acetylenes. A mechanistic study of inactivation of a plant lauric acid-hydroxylase. J Biol Chem. 272:414–421.
   PubMed Web of Science ®Google Scholar
• Herz R, Koelz HR, Haemmerli UP, Benes I, Blum AL. 1978. Inhibition of hepatic demethylation of aminopyrine by oral contraceptive steroids in humans. Eur J Clin Invest. 8:27–30.
   PubMed Web of Science ®Google Scholar
• Hopkins NE, Foroozesh MK, Alworth WL. 1992. Suicide inhibitors of cytochrome P450 1A1 and P450 2B1. Biochem Pharmacol. 44:787–796.
   PubMed Web of Science ®Google Scholar
• Johnston JO, Wright CL, Leeson GA. 1991. Regioselectivity of metabolic activation of acetylenic steroids by hepatic cytochrome P450 isozymes. Steroids. 56:180–184.
   PubMed Web of Science ®Google Scholar
• Kanhai W, Koob M, Dekant W, Henschler D. 1991. Metabolism of 14C-dichloroethyne in rats. Xenobiotica. 21:905–916.
   PubMed Web of Science ®Google Scholar
• Kent UM, Lin H, Mills DE, Regal KA, Hollenberg PF. 2006. Identification of 17-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. Chem Res Toxicol. 19:279–287.
   PubMed Web of Science ®Google Scholar
• Kent UM, Sridar C, Spahlinger G, Hollenberg PF. 2008. Modification of serine 360 by a reactive intermediate of 17-ethynylestradiol results in mechanism-based inactivation of cytochrome P450s 2B1 and 2B6. Chem Res Toxicol. 21:1956–1963.
   PubMed Web of Science ®Google Scholar
• Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, Hollenberg PF. 2002. Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp Ther. 300:549–558.
   PubMed Web of Science ®Google Scholar
• Khan KK, He YQ, Correia MA, Halpert JR. 2002. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metab Dispos. 30:985–990.
   PubMed Web of Science ®Google Scholar
• Komives EA, Ortiz de Montellano PR. 1987. Mechanism of oxidation of bonds by cytochrome P450. Electronic requirements of the transition state in the turnover of phenylacetylenes. J Biol Chem. 262:9793–9802.
   PubMed Web of Science ®Google Scholar
• Kunze KL, Mangold BLK, Wheeler C, Beilan HS, Ortiz de Montellano PR. 1983. The cytochrome P-450 active site. Regiospecificity of prosthetic heme alkylation by olefins and acetylenes. J Biol Chem. 258:4202–4207.
   PubMed Web of Science ®Google Scholar
• Lewars EG. 1983. Oxirenes. Chem Rev. 83:519–534.
   Web of Science ®Google Scholar
• Lewis RD, Garcia-Borrás M, Chalkley MJ, Buller AR, Houk KN, Kan SBJ, Arnold FH. 2018. Catalytic iron-carbene intermediate revealed in a cytochrome c carbene transferase. Proc Natl Acad Sci USA. 115:7308–7313.
   PubMed Web of Science ®Google Scholar
• Lin HL, Hollenberg PF. 2007. The inactivation of cytochrome P450 3A5 by 17-ethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein. J Pharmacol Exp Therap. 321:276–287.
   PubMed Web of Science ®Google Scholar
• Lin HL, Kent UM, Hollenberg PF. 2002. Mechanism-based inactivation of cytochrome P450 3A4 by 17-ethynylestradiol: evidence for heme destruction and covalent binding to protein. J Pharmacol Exp Therap. 301:160–167.
   PubMed Web of Science ®Google Scholar
• Lin HL, Kent UM, Zhang H, Waskell L, Hollenberg PF. 2004. The functional role of threonine-205 in the mechanism-based inactivation of P450 2B1 by two ethynyl substrates: the importance of the F helix in catalysis. J Pharmacol Exp Ther. 311:855–863.
   PubMed Web of Science ®Google Scholar
• Lin HL, Zhang H, Hollenberg PF. 2009. Metabolic activation of mifepristone [RU486; 17-hydroxy-11-(4-dimethylaminophenyl)-17-(1-propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6. J Pharmacol Exp Therap. 329:26–37.
   PubMed Web of Science ®Google Scholar
• Lin HL, Zhang H, Hollenberg PF. 2018. Formation of both heme and apoprotein adducts contributes to the mechanism-based inactivation of human CYP2J2 by 17-ethynylestradiol. Drug Metab Dispos. 46:813–822.
   PubMed Web of Science ®Google Scholar
• Lin HL, Zhang H, Jushchyshyn M, Hollenberg PF. 2010. Covalent modification of Thr302 in cytochrome P450 2B1 by the mechanism-based inactivator 4-tert-butylphenylacetylene. J Pharmacol Exp Therap. 333:663–669.
   PubMed Web of Science ®Google Scholar
• Lin HL, Zhang H, Pratt-Hyatt MJ, Hollenberg PF. 2011. Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene. Drug Metab Dispos. 39:2431–2439.
   PubMed Web of Science ®Google Scholar
• Lin HL, Zhang H, Walker V, D’Agostino J, Hollenberg PF. 2017. Heme modification contributes to the mechanism-based inactivation of human cytochrome P450 2J2 by two terminal acetylenic compounds. Drug Metab Dispos. 45:990–999.
   PubMed Web of Science ®Google Scholar
• Lin HL, Zhang H, Waskell L, Hollenberg PF. 2003. Threonine-205 in the F helix of P450 2B1 contributes to androgen 16-hydroxylation activity and mechanism-based inactivation. J Pharmacol Exp Therap. 306:744–751.
   PubMed Web of Science ®Google Scholar
• Mak PJ, Zhang H, Hollenberg PF, Kincaid JR. 2010. Defining the structural consequences of mechanism-based inactivation of mammalian cytochrome P450 2B4 using resonance Raman spectroscopy. J Am Chem Soc. 132:1494–1495.
   PubMed Web of Science ®Google Scholar
• Mawhinney RC, Goddard JD. 2003. Assessment of density functional theory for the prediction of the nature of the oxirene stationary point. J Molec Struct. 629:263–270.
   Web of Science ®Google Scholar
• McMahon RE, Turner JC, Whitaker GW, Sullivan HR. 1981. Deuterium-isotope effect in the biotransformation of 4-ethynylbiphenyls to 4-biphenylacetic acids by rat hepatic microsomes. Biochem Biophys Res Commun. 99:662–667.
   PubMed Web of Science ®Google Scholar
• Metcalf BW, Wright CL, Burkhart JP, Johnston JO. 1981. Substrate-induced inactivation of aromatase by allenic and acetylenic steroids. J Am Chem Soc. 103:3221–3222.
   Web of Science ®Google Scholar
• Mutlib A, Chen H, Shockcor J, Espina R, Chen S, Cao K, Du A, Nemeth G, Prakash S, Gan L-S. 2000. Characterization of novel glutathione adducts of a non-nucleoside reverse trascriptase inhibitor, (S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-3,4-dihydro-2(1H)-quinazolinone (DPC 961), in rats. Possible formation of an oxirene metabolic intermediate from a disubstituted alkyne. Chem Res Toxicol. 13:775–784.
   PubMed Web of Science ®Google Scholar
• Nagahisa A, Spencer RW, Orme-Johnson WH. 1983. Acetylenic mechanism-based inhibitors of cholesterol side chain cleavage by cytochrome P-450scc. J Biol Chem. 258:6721–6723.
   PubMed Web of Science ®Google Scholar
• O’Malley K, Stevenson IH, Crooks J. 1972. Impairment of human drug metabolism by oral contraceptive steroids. Clin Pharmacol Ther. 13:552–557.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR. 1985. Alkenes and alkynes. In: Anders MW, editor. Bioactivation of foreign compounds. New York (NY): Academic Press; p. 121–155.
   Google Scholar
• Ortiz de Montellano PR. 2015. Substrate oxidation by cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450: structure, mechanism, and biochemistry. 4th ed. New York (NY): Springer; p. 111–176.
   Google Scholar
• Ortiz de Montellano PR, Komives EA. 1985. Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450. J Biol Chem. 260:3330–3336.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Kunze KL. 1980a. Occurrence of a 1,2-shift during enzymatic and chemical oxidation of a terminal acetylene. J Am Chem Soc. 102:7373–7375.
   Web of Science ®Google Scholar
• Ortiz de Montellano PR, Kunze KL. 1980b. Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates. J Biol Chem. 255:5678–5685.
   Web of Science ®Google Scholar
• Ortiz de Montellano PR, Kunze K. 1981a. Shift of the acetylenic hydrogen during chemical and enzymatic oxidation of the biphenylacetylene triple bond. Arch Biochem Biophys. 209:710–712.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Kunze KL. 1981b. Cytochrome P-450 inactivation: structure of the prosthetic heme adduct with propyne. Biochemistry. 20:7266–7271.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Beilan HS, Mathews JM. 1982a. Alkylation of the prosthetic heme in cytochrome P-450 during oxidative metabolism of the sedative-hypnotic ethchlorvynol. J Med Chem. 25:1174–1179.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Kunze KL, Beilan HS, Wheeler C. 1982b. Destruction of cytochrome P-450 by vinyl fluoride, fluroxene, and acetylene. Evidence for a radical intermediate in olefin oxidation. Biochemistry. 21:1331–1339.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Kunze KL, Yost GS, Mico BA. 1979. Self-catalyzed destruction of cytochrome P-450: covalent binding of ethynyl sterols to prosthetic heme. Proc Natl Acad Sci USA. 76:746–749.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Reich NO. 1984. Specific inactivation of hepatic fatty acid hydroxylases by acetylenic fatty acids. J Biol Chem. 259:4136–4141.
   PubMed Web of Science ®Google Scholar
• Palmer CJ, Cole LM, Smith IH, Moss MDV, Casida JE. 1991. Silylated 1-(4-ethynyl]phenyl)-2,6,7-trioxabicyclo[2,2,2]octanes: Structural features and mechanisms of proinsecticidal action and selective toxicity. J Agric Food Chem. 39:1335–1341.
   Web of Science ®Google Scholar
• Palmer KH, Feierabend JF, Baggett B, Wall ME. 1969. Metabolic removal of a 17-ethynyl group from the antifertility steroid, norethindrone. J Pharmacol Exp Therap. 167:217–222.
   PubMed Web of Science ®Google Scholar
• Podoll T, Pearson PG, Evarts J, Ingallinera T, Bibikova E, Sun H, Gohdes M, Cardinal K, Sanghvi M, Slatter JG. 2019. Bioavailability, biotransformation, and excretion of the covalent Bruton tyrosine kinase inhibitor acalabrutinib in rats, dogs, and humans. Drug Metab Dispos. 47:145–154.
   PubMed Web of Science ®Google Scholar
• Raitano LA, Slikker W Jr, Hill DE, Hadd HE, Cairns T, Helton ED. 1981. Ethynyl cleavage of 17 alpha-ethynylestradiol in the rhesus monkey. Drug Metab Dispos. 9:129–134.
   PubMed Web of Science ®Google Scholar
• Regal KA, Schrag ML, Kent UM, Wienkers LC, Hollenberg PF. 2000. Mechanism-based inactivation of cytochrome P450 2B1 by 7-ethynylcoumarin: verification of apo-P450 adduction by electrospray ion trap mass spectrometry. Chem Res Toxicol. 13:262–270.
   PubMed Web of Science ®Google Scholar
• Reilly PEB, Gomi RJ, Mason SR. 1999. Mechanism-based inhibition of rat liver microsomal diazepam C3-hydroxylase by mifepristone associated with loss of spectrally detectable cytochrome P450. Chemico-Biol Interact. 118:39–49.
   PubMed Web of Science ®Google Scholar
• Roberts ES, Alworth WL, Hollenberg PF. 1998. Mechanism-based inactivation of cytochromes P450 2E1 and 2B1 by 5-phenyl-1-pentyne. Arch Biochem Biophys. 354:295–302.
   PubMed Web of Science ®Google Scholar
• Roberts ES, Ballou DP, Hopkins NE, Alworth WL, Hollenberg PF. 1995a. Mechanistic studies of 9-ethynylphenanthrene-inactivated cytochrome P450 2B1. Arch Biochem Biophys. 323:303–312.
   PubMed Web of Science ®Google Scholar
• Roberts ES, Hopkins NE, Alworth WL, Hollenberg PF. 1993. Mechanism-based inactivation of cytochrome P450 2B1 by 2-ethynylnaphthalene: identification of an active-site peptide. Chem Res Toxicol. 6:470–479.
   PubMed Web of Science ®Google Scholar
• Roberts ES, Hopkins NE, Foroozesh M, Alworth WL, Halpert JR, Hollenberg PF. 1997. Inactivation of cytochrome P450s 2B1, 2B4, 2B6, and 2B11 by arylalkynes. Drug Metab Dispos. 25:1242–1248.
   PubMed Web of Science ®Google Scholar
• Roberts ES, Hopkins NE, Zaluzec EJ, Gage DA, Alworth WL, Hollenberg PF. 1994. Identification of active-site peptides from 3H-labeled 2-ethynylnaphthalene-inactivated P450 2B1 and 2B4 using amino acid sequencing and mass spectrometry. Biochemistry. 33:3766–3771.
   PubMed Web of Science ®Google Scholar
• Roberts ES, Hopkins NE, Zaluzec EJ, Gage DA, Alworth WL, Hollenberg PF. 1995b. Mechanism-based inactivation of cytochrome P450 2B1 by 9-ethynylphenanthrene. Arch Biochem Biophys. 323:295–302.
   PubMed Web of Science ®Google Scholar
• Rose PA, Cutler AJ, Irvine NM, Shaw AC, Squires TM, Loewen MK, Abrams SR. 1997. 8’-Acetylene ABA: an irreversible inhibitor of ABA 8’-hydroxylase. Bioorg Med Chem Lett. 7:2543–2546.
   Web of Science ®Google Scholar
• Sacher RM, Metcalf RL, Fukuto TR. 1968. Propynyl naphthyl ethers as selective carbamate synergists. J Agric Food Chem. 16:779–786.
   Web of Science ®Google Scholar
• Salaün JP, Simon A, Durst F, Reich NO, Ortiz de Montellano PR. 1988. Differential inactivation of plant lauric acid omega- and in-chain-hydroxylases by terminally unsaturated fatty acids. Arch Biochem Biophys. 260:540–545.
   PubMed Web of Science ®Google Scholar
• Salmon J, Coussediere D, Cousty C, Raynaud JP. 1983. Pharmacokinetics and metabolism of moxestrol in humans. J Steroid Biochem. 19:565–573.
   Google Scholar
• Schmid SE, Au WYW, Hill DE, Kadlubar FF, Slikker W. 1983. Cytochrome P-450-dependent oxidation of the 17-ethynyl group of synthetic steroids. D-Homoannulation or enzyme inactivation. Drug Metab Disp. 11:531–536.
   PubMed Web of Science ®Google Scholar
• Sharma U, Roberts ES, Hollenberg PF. 1996. Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline. Drug Metab Dispos. 24:669–675.
   PubMed Web of Science ®Google Scholar
• Shimada T, Murayama N, Okada K, Funae Y, Yamazaki H, Guengerich FP. 2007. Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors. Chem Res Toxicol. 20:489–496.
   PubMed Web of Science ®Google Scholar
• Shirane N, Sui Z, Peterson JA, Ortiz de Montellano PR. 1993. Cytochrome P450BM-3 (CYP102): regiospecificity of oxidation of omega-unsaturated fatty acids and mechanism-based inactivation . Biochemistry. 32:13732–13741.
   PubMed Web of Science ®Google Scholar
• Simonneaux G, Le Maux P. 2006. Carbene complexes of heme protein and iron porphyrin models. Top Organomet Chem. 17:83–122.
   Google Scholar
• Sisenwine SF, Kimmel HB, Liu AL, Ruelius HW. 1973. Urinary metabolites of DL-norgestrel in women. Acta Endocrinol.73:91–104.
   PubMedGoogle Scholar
• Sisenwine SF, Kimmel HB, Liu AL, Ruelius HW. 1979. The metabolic disposition of norgestrel in female rhesus monkeys. Drug Metab Dispos. 7:1–6.
   PubMed Web of Science ®Google Scholar
• Siu ECK, Tyndale RF. 2008. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Therap. 324:992–999.
   PubMed Web of Science ®Google Scholar
• Sridar C, Kenaan C, Hollenberg PF. 2012. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts. Drug Metab Disp. 40:2256–2266.
   PubMed Web of Science ®Google Scholar
• Sridar C, Kent UM, Noon K, McCall A, Alworth B, Foroozesh M, Hollenberg PF. 2008. Differential inhibition of cytochromes P450 3A4 and 3A5 by the newly synthesized coumarin derivatives 7-coumarin propargyl ether and 7-(4-trifluoromethyl)coumarin propargyl ether. Drug Metab Dispos. 36:2234–2243.
   PubMed Web of Science ®Google Scholar
• Strobel SM, Szklarz GD, He YQ, Foroozesh M, Alworth WL, Roberts ES, Hollenberg PF, Halpert JR. 1999. Identification of selective mechanism-based inactivators of cytochromes P-450 2B4 and 2B5, and determination of the molecular basis for differential susceptibility. J Pharmacol Exp Therap. 290:445–451.
   PubMed Web of Science ®Google Scholar
• Su H, Ma G, Liu Y. 2018. Theoretical insights into the mechanism and stereoselectivity of olefin cyclopropanation catalyzed by two engineered cytochrome P450 enzymes. Inorg Chem. 57:11738–11745.
   PubMed Web of Science ®Google Scholar
• Subramanian R, Tam J, Aidasani D, Reid DL, Skiles GL. 2011. Novel cytochrome P450 bioactivation of a terminal phenyl acetylene group: formation of a one-carbon loss benzaldehyde and other oxidative products in the presence of N-acetyl cysteine or glutathione. Chem Res Toxicol. 16:677–686.
   Google Scholar
• Sullivan HR, Roffey P, McMahon RE. 1979. Biotransformation of 4'-ethynl-2-fluorobiphenyl in the rat. In vitro and in vivo studies. Drug Metab Dispos. 7:76–80.
   PubMed Web of Science ®Google Scholar
• Vacek G, Galbraith JM, Yamaguchi Y, Schaefer HF, III, Nobes RH, Scott AP, Radom L. 1994. Oxirene: to be or not to be? J Phys Chem. 98:8660–8665.
   Web of Science ®Google Scholar
• von Weyman LB, Blobaum AL, Hollenberg PF. 2004a. The mechanism-based inactivation of P450 2B4 by tert-butyl 1-methyl-2-propynyl ether: structural determination of the adducts to the P450 heme. Arch Biochem Biophys. 425:95–105.
   PubMed Web of Science ®Google Scholar
• von Weyman LB, Sridar C, Hollenberg PF. 2004b. Identification of amino acid residues involved in the inactivation of cytochrome P450 2B1 by two acetylenic compounds: the role of three residues in nonsubstrate recognition sites. J Pharmacol Exp Therap. 311:71–79.
   PubMed Web of Science ®Google Scholar
• Wade A, Symons AM, Martin L, Parke DV. 1979. Metabolic oxidation of the ethynyl group in 4-ethynylbiphenyl. Biochem J. 184:509–517.
   PubMed Web of Science ®Google Scholar
• Wade A, Symons AM, Martin L, Parke DV. 1980. The metabolic oxidation of the ethynyl group in 4-ethynylbiphenyl in vitro. Biochem J. 188:867–872.
   PubMed Web of Science ®Google Scholar
• White I. 1978. Metabolic activation of acetylenic substituents to derivatives in the rat causing the loss of hepatic cytochrome P-450 and haem. Biochem J. 174:853–861.
   PubMed Web of Science ®Google Scholar
• White I. 1980. Structure-activity relationships in the destruction of cytochrome P-450 mediated by certain ethynyl-substituted compounds in rats. Biochem Pharmacol. 29:3253–3255.
   PubMed Web of Science ®Google Scholar
• White I. 1981. Destruction of liver haem by norethindrone. Conversion into green pigments. Biochem J. 196:575–583.
   PubMed Web of Science ®Google Scholar
• White I. 1982. Biliary excretion of green pigments produced by norethindrone in the rat. Biochem Pharmacol. 31:1337–1342.
   PubMed Web of Science ®Google Scholar
• White INH, Campbell JB, Farmer PB, Bailey E, Nam NH, Thang DC. 1984. Metabolic activation of acetylenes. Covalent binding of [1,2-14C]octyne to protein, DNA, and haem in vitro and the protective effects of certain thiol compounds. Biochem J. 220:85–94.
   PubMed Web of Science ®Google Scholar
• Williams MC, Helton ED, Goldzieher JW. 1975. The urinary metabolites of 17-ethynylestradiol-9,11-3H in women. Chromatographic profiling and identification of ethynyl and non-ethynyl compounds. Steroids. 25:229–246.
   PubMed Web of Science ®Google Scholar
• Wolf CR, Mansuy D, Nastainczyk W, Deutschmann G, Ullrich V. 1977. The reduction of polyhalogenated methanes by liver microsomal cytochrome P450. Molec Pharmacol. 13:698–705.
   PubMed Web of Science ®Google Scholar
• Yun CH, Hammons GJ, Jones G, Martin MV, Hopkins NE, Alworth WL, Guengerich FP. 1992. Modification of cytochrome P4501A2 enzymes by the mechanism-based inactivator 2-ethynylnaphthalene. Biochemistry. 31:10556–10563.
   PubMed Web of Science ®Google Scholar
• Zeller KP, Blocher A, Haiss P. 2004. Oxirene participation in the photochemical Wolff rearrangement. MROC. 1:291–308.
   Google Scholar
• Zhang H, Gay SC, Shah MB, Foroozesh M, Liu J, Osawa Y, Zhang Q, Stout CD, Halpert JR, Hollenberg PF. 2013. Potent mechanism-based inactivation of cytochrome P450 2B4 by 9-ethynylphenanthrene: implications for allosteric modulation of cytochrome P450 catalysis. Biochemistry. 52:355–364.
   PubMed Web of Science ®Google Scholar
• Zhang H, Lin H, Kenaan C, Hollenberg PF. 2011. Targeting of the highly conserved threonine 302 residue of cytochromes P450 2B family during mechanism-based inactivation by aryl acetylenes. Arch Biochem Biophys. 507:135–143.
   PubMed Web of Science ®Google Scholar
• Zhang H, Lin H, Walker VJ, Hamdane D, Hollenberg PF. 2009. tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance. J Pharmacol Exp Therap. 331:1011–1018.
   Google Scholar
• Zhao H, Li S, Yang Z, Peng Y, Chen X, Zheng J. 2018. Identification of ketene-reactive intermediate of erlotinib possibly responsible for inactivation of P450 enzymes. Drug Metab Dispos. 46:442–450.
   PubMed Web of Science ®Google Scholar